IMG Wealth Management Inc. Makes New Investment in MiMedx Group, Inc. (NASDAQ:MDXG)

IMG Wealth Management Inc. bought a new position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,916 shares of the company’s stock, valued at approximately $28,000.

A number of other large investors have also recently added to or reduced their stakes in MDXG. JPMorgan Chase & Co. boosted its position in MiMedx Group by 265.4% during the third quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock worth $1,757,000 after purchasing an additional 215,995 shares during the period. Jane Street Group LLC boosted its position in MiMedx Group by 133.6% during the third quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock worth $1,806,000 after purchasing an additional 174,797 shares during the period. Barclays PLC boosted its position in MiMedx Group by 163.9% during the third quarter. Barclays PLC now owns 262,449 shares of the company’s stock worth $1,550,000 after purchasing an additional 163,005 shares during the period. Charles Schwab Investment Management Inc. boosted its position in MiMedx Group by 6.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company’s stock worth $8,483,000 after purchasing an additional 92,726 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in MiMedx Group during the fourth quarter worth approximately $887,000. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Up 1.5 %

MDXG opened at $8.04 on Tuesday. MiMedx Group, Inc. has a 1-year low of $5.47 and a 1-year high of $10.14. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 14.62 and a beta of 1.97. The business has a 50 day moving average of $8.44 and a 200-day moving average of $7.83.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The company had revenue of $92.91 million during the quarter, compared to analysts’ expectations of $89.42 million. As a group, sell-side analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price objective on shares of MiMedx Group in a research report on Thursday, February 27th.

Insider Activity at MiMedx Group

In related news, CAO William Frank Iv Hulse sold 81,446 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $7.80, for a total value of $635,278.80. Following the completion of the transaction, the chief accounting officer now directly owns 494,774 shares in the company, valued at approximately $3,859,237.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the transaction, the insider now owns 310,836 shares of the company’s stock, valued at $2,452,496.04. The trade was a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 142,259 shares of company stock worth $1,116,170. 1.30% of the stock is owned by corporate insiders.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.